A Randomised, Double Blind, Placebo Controlled, Single Ascending Dose, Phase I Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PG102 (Anti-CD40 Monoclonal Antibody) In Patients With Active Psoriatic Arthritis

Trial Profile

A Randomised, Double Blind, Placebo Controlled, Single Ascending Dose, Phase I Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PG102 (Anti-CD40 Monoclonal Antibody) In Patients With Active Psoriatic Arthritis

Discontinued
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2012

At a glance

  • Drugs FFP 102 (Primary)
  • Indications Psoriatic arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Jun 2010 Actual patient number (17) added as reported by ClinicalTrials.gov.
    • 03 Jun 2010 Planned end date changed from 1 Nov 2009 to 1 May 2010 as reported by ClinicalTrials.gov.
    • 03 Jun 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top